Biologics right now are scheduled. They're regulated well in our regulations for the drugs. For the most part, companies will keep going through that pathway.
For example, some of the stem cell research and advanced cell work that we're seeing done in hospitals may not, with the manufacturing model, fit well within the biologics regulations. In that case, we would take a species of biologics and move them into that schedule so that we could tailor some of the requirements.
Many of the requirements will remain the same. You always need to show that it works the way we think it should, that it's safe within the disease it's treating and that there's a high-quality manufacturer. All those ground rules will still apply, but this is where again we need to be flexible with the biologics.
Biologics may thus straddle both their home, which they're in right now, but also this new pathway.